Learn about the financial strain caused by the skyrocketing demand and costs of GLP-1 drugs, and how health plans and providers are struggling to balance it.

Compounding pharmacies aren’t the only makers of off-brand versions of Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound. The ...

Related Cosmetic surgeons try to correct 'Ozempic face' for weight-loss drug users Massive study looks at benefits, risks of ...

Ozempic, Wegovy, Saxenda, Trulicity: These and other GLP1-RA diabetes/weight-loss meds can also boost outcomes for fo ...

January 2025 kicked off with a wave of impactful biotech deals, setting the stage for an exciting year of innovation.

Request To Download Free Sample of This Strategic Report @ Highlighted with 41 tables and 85 figures, this 159-page report ?Asia Pacific Biopharmaceuticals Market 2023-2033 by Product Type, Testing ...

Regeneron reported Q4 2024 earnings today and declared its first-ever dividend of $0.88 per quarter. Click here to know what ...

The GLP-1 drug, exenatide, has no positive impact on the movement, symptoms or brain imaging of people with Parkinson’s, finds a new study led by UCL researchers.

GLP-1 receptor agonists were more cardioprotective in younger people, but reduced HbA1c more with age. The age of type 2 ...

While Novo Nordisk (NVO) and Eli Lilly (NYSE:LLY) still rule the weight-loss drug market with their respective GLP-1 medications, competition could soon be heating up as rival products near ...

Subin Baral, EY global life sciences deals leader, told GEN M&A deals are expected to increase in 2025, driven by biopharmas that are eager to recoup revenues they expect to lose as their aging ...

Roche Holding AG delivered a strong set of 2024 earnings. Guidance for 2025 suggests this will be a transitional year ahead, ...